

PTC Therapeutics, Inc. Investor Relations Department 100 Corporate Ct. South Plainfield, NJ 07080 United States

Visit IR website ☐ Sign-up for Email alerts ☐

# NASDAQ: PTCT Last Trade: 21.55 Trade Time: 4:00 PM ET Jul 24, 2017 Change: 0.11 ♣ (+0.513%) Day Range 20.53 - 21.62 52-Week Range 4.03 - 21.65 Volume 805,444

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

# **Company Profile**

PTC Therapeutics, Inc. is committed to serving the interests of our shareholders. This part of our website includes corporate governance documents, press releases, financial information and other documents to help shareholders better understand who we are and what we do.

... (more)

# **Stock Performance**



## Press Releases [View all ]

Jul 24, 2017

PTC Therapeutics Announces Promotion of Dr. Joseph McIntosh to Senior Vice President and Head of Clinical Development

Jul 18, 2017

PTC Therapeutics Announces Publication of Data from ACT DMD in The Lancet

Jul 1, 2017

Preliminary Phase 2 Data from Spinal Muscular Atrophy Program Presented at CureSMA Conference

Jun 30, 2017

PTC Therapeutics Reports Inducement
Grants Under Nasdag Listing Rule 5635(c)(4)

Jun 22, 2017

New Analyses of Translarna™ (ataluren)

Data from ACT DMD Presented at the 12th

Annual European Pediatric Neurology Society

Congress

## Financials [View all]

Mar 16, 2017 Annual Report (10-K)

Apr 28, 2017
Proxy Statement (DEF 14A)

May 8, 2017 Quarterly Report (10-Q)

Nov 3, 2016 Quarterly Report (10-Q)

Aug 4, 2016
Quarterly Report (10-Q)